The results of imatinib therapy for patients with primary eosinophilic disorders

Eur J Haematol. 2006 Jun;76(6):535-6. doi: 10.1111/j.1600-0609.2006.00652.x. Epub 2006 Apr 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Drug Evaluation
  • Eosinophilia / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / genetics
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Myeloproliferative Disorders / drug therapy
  • Neoplasm Proteins / analysis
  • Neoplasm Proteins / genetics
  • Oncogene Proteins, Fusion / analysis
  • Oncogene Proteins, Fusion / genetics
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor alpha / analysis
  • Receptor, Platelet-Derived Growth Factor alpha / genetics
  • Treatment Outcome
  • mRNA Cleavage and Polyadenylation Factors / analysis
  • mRNA Cleavage and Polyadenylation Factors / genetics

Substances

  • Antineoplastic Agents
  • Benzamides
  • Biomarkers, Tumor
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha